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Abstract 
Background and purpose: Dysregulated miRNAs play an important role in many malignant tumors. However, 
elucidating the roles of miRNAs in cancer biology, especially in epithelial cancers, remains an ongoing process. In this 
study, we identified the differentially expressed miR-645 in the progressing of head and neck squamous cell carci-
noma (HNSCC) and investigated its biological function.
Methods: The association between clinicopathological parameters and the expression levels of the candidated miR-
NAs were analyzed by using the Kaplan–Meier survival analysis. The cell growth, invasion and migration potential, and 
clone formation were observed to detect the functions of the miRNAs in HNSCC cells.
Results: In the 34 HNSCC tissues with lymph node metastasis, the expression level of miR-645 was 0.54 ± 0.12, and 
the expression level was 0.22 ± 0.05 in the 28 tissues with non lymph node metastasis (p = 0.017). In patients with 
HNSCC, higher level of miR-645 expression significantly correlates with worse overall survival (p = 0.04). Ectopic 
expression of miR-645 promoted cell invasion and migration.
Conclusions: miR-645 play a key role in cell invasion and metastasis and their expression correlates with overall sur-
vival in the patients with HNSCC.
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Background
MicroRNAs (miRNAs) are endogenous RNAs that play 
important gene-regulatory roles in animals via sequence-
specific interactions with the 3′UTR of cognate mRNA 
targets, causing suppression of translation and mRNA 
decay [1, 2]. Nucleotides 2–7, from the 5′ end of the 
miRNAs, are referred to as the “seed” and are critical for 
hybridization to the targets [3], It has been firmly estab-
lished that miRNAs regulate many key cellular processes 
such as cell growth, differentiation and apoptosis [4, 5]. 
Subsets of miRNAs have been identified as potential 
diagnostic and prognostic markers in malignant tumors 
[6–8]. Many evidences suggest that the regulatory capac-
ity of miRNAs is dysregulated and exploited in malignant 
tumors [9]. Several miRNAs are up-regulated in specific 
tumors appears a general trait of human cancers which 
playing a causal role in the transformed phenotype [10–
12], and the mechanisms are remain to be known further. 
Although the number of verified human miRNAs is still 
expanding, the functions of only a few of them have been 
described.
Head and neck squamous cell carcinoma (HNSCC) 
ranks sixth among cancers worldwide [13], includes 
tumors of the oral cavity, oropharynx, and larynx. Sur-
vival rates for HNSCC have remained unchanged 
throughout the last three decades, and half of all cases 
die within 5  years of diagnosis [11]. The presence of 
lymph node metastasis affects more than 50 % of HNSCC 
patients and it is one of the most important prognostic 
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indicators associated with poor long survival rates [14, 
15]. There are some biomarkers for the classification 
diagnosis, individual treatment and prognosis of HNSCC 
investigated by miRNAs array and studies have shown 
altered miRNAs profiles in HNSCC compared to their 
normal tissue [16–21]. miR-645 has been reported to be 
disrupt-expression in pathological states [22–25], how-
ever, the role of miR-645 in metastasis of cancer has not 
been reported.
In this study, we examined the expression of miR-645 
in HNSCC samples by gene chips and further confirmed 
in HNSCC samples and HNSCC cell lines using real-time 
PCR. We found that miR-645 levels were up-regulated 
in HNSCC tissues and highly invasive cell lines. Further-
more, we have investigated the mechanism of miR-645 in 
HNSCC cancer cell lines. These results show that exog-
enous overexpression of miR-645 promotes the invasion 
and migration of HNSCC cells in vitro.
Methods
Cell culture
The human HNSCC cell lines, HN4 and HN12 were 
kindly provided by Shanghai Key Laboratory of Stoma-
tology [26–30]. These cell lines were cultured in DMEM 
supplemented with 10  % heat-inactivated FBS (GIBCO 
BRL, NY, USA), penicillin (100  units/ml) and strep-
tomycin (100 μg/ml) at 37  °C in a humidified 5  % CO2 
atmosphere.
Tissue samples and reagents
Tissue samples from patients undergoing curative treat-
ment for definitely diagnosed HNSCC were obtained by 
surgery, with half of each sample quickly frozen in liquid 
nitrogen and stored at −80 °C until use and the other half 
embedded in paraffin for pathological examination. All 
patients selected in the study were informed consent in 
advance. In parallel, a separate cohort of 47 patients also 
was assembled from a large pool of patients in the data-
base based on histologic diagnosis of HNSCC who had 
undergone radical surgery. We retrospectively reviewed 
the medical records of patients with HNSCC. In this 
study, we retrospectively reviewed the medical records of 
patients. Total RNAs were extracted from paraffin blocks 
using the high pure miRNA isolation kit according to the 
manufacturer’s protocol (Roche, Switzerland) before fur-
ther analysis.
Both the miR-645 inhibitor and its mimics were pur-
chased from GenePharma (Shanghai, China). The high 
pure miRNA isolation kit was purchased from Roche 
(Basel, Switzerland). The miRcute miRNA qPCR detec-
tion kit and miRcute miRNA qPCR detection kit were 
purchased from TIANGEN BIOTECH (Beijing, China).
Invasion assays and wound‑healing experiment
In vitro invasion assays were performed to analyze the 
invasive potential. A total of 8  ×  104 various cells in 
200 μl serum-free DMEM medium were plated onto BD 
BioCoat™ Matrigel™ Invasion Chamber (8 μm pore size; 
BD Biosciences) and the lower chamber was immediately 
filled with 500 μl of DMEM medium with 10 % FBS as a 
chemoattractant. After 24 h of incubation in a humidified 
atmosphere containing 5 % CO2 at 37 °C, the non-invading 
cells are removed from the upper surface of the membrane 
by a cotton swab and the membranes were then fixed with 
methanol and stained by 0.2 % crystal violet. For wound-
healing experiments, cells were plated in 6-well plates, 
transfected as indicated, and cultured to confluency. Cells 
were serum-starved and scraped with a P200 tip (time 0), 
and the number of migrating cells is counted from pictures 
(5 fields) taken at the indicated time points.
Clony formation
Twenty-four hours after transfection, HNSCC cells 
(1 × 105 cells per plate) were plated in 100-mm culture 
dishes and incubated with 600 μg/ml G418 in final con-
centration for 14  days to allow colonies formation. The 
colonies were then washed twice with PBS, fixed with 
70  % ethanol and stained with Coomassie Blue. Colo-
nies of more than 50 cells were counted under a dissect-
ing microscope. The data from colony formation were 
showed as mean ±  SD from at least three independent 
experiments, each being performed in triplicate.
Statistical analysis
Statistical analyses for real-time PCR and the in  vitro 
analysis were performed with software from SPSS 13.0 
(standard version 13.0; SPSS Inc., Chicago, IL, USA). 
The results of the cell proliferation assay, colony forma-
tion assay, and in vitro invasion assay were evaluated by 
Student’s t tests. Patients were divided in two groups 
based on the median of the miR-645 expression values. 
Tumors were then classified as high miR-645 group if the 
expression value was equal to or above the median and 
as low miR-645 group if the expression value was below 
the median. The correlation between miR-645 expression 
and the disease-free survival probability were estimated 
by using Kaplan–Meier survival analysis. A P < 0.05 was 
taken as the level of significance.
Results
The association of miR‑645 expression with metastatic 
rates in patients with HNSCC
We first measured mature miR-645 levels in a group 
of tissue specimens from the HNSCC patients. In the 
76 HNSCC tissues with lymph node metastasis, the 
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expression level of miR-645 was 2.71  ±  0.24, and the 
expression level was 1.58  ±  0.23 in the 51 tissues with 
non lymph node metastasis (p  =  0.001, Fig.  1a). The 
results showed that the miR-645 expression level in the 
primary HNSCC samples with lymph node metastasis 
was significantly higher than that in the tissues without 
lymph node metastasis. The correlations between the 
miR-645 expression level and clinical pathological char-
acteristics of are summarized in Table 1. Statistically sig-
nificant associations between the miR-645 expression 
levels and metastatic rates were observed. In the HNSCC 
tissues with severe histological signs (vascular emboli, 
perineural invasion, diffuse infiltration), the expression 
level of miR-645 was also significantly higher than the 
expression level in the tissues with non-severe histologi-
cal signs (Fig.  1c–e). However, there was no significant 
correlation between the expression level of miR-645 and 
age, sex, tumor size, site, smoking history, alcohol history 
(Table 1).
We next measured mature miR-645 levels in a collec-
tion of HNSCC patients with clinical history. Patients 
were divided in two groups, with, respectively high or 
low levels of miR-645. Remarkably, when tested using the 
Kaplan–Meier survival analysis, the miR-645 “low” group 
displayed a significant longer disease-free survival when 
compared to the “high” group (Fig. 1b). These data sug-
gested a possible link between miR-645 expression and 
tumor progression.
miR‑645 promotes cell proliferation
HN4 and HN12 cell lines were established from pri-
mary HNSCC tissue and the lymph node metastatic tis-
sue from the same patient, respectively. We used these 
cell lines to investigate how gain or loss of function of 
miR-645 impacted cell biological behavior. The HN12 
cells displayed high migration capacities and contained 
a relatively high level of miR-645 (Fig.  2a). First, we 
assessed the growth of miR-645-transfected and miR-
NC-transfected HN4 cells after transient transfection. 
As shown in Fig.  2b, miR-645 was able to increase the 
proliferation of miR-645-transfected cells compared 
with miR-NC-transfected cells significantly at day 3 and 
5 (P < 0.05, Student’s t test) (Fig. 2b). We further tested 
if endogenous expression of miR-645 was required for 
Fig. 1 Clinical association of miR-645 with HNSCC patients. a Mature miR-645 levels were measured in HNSCC samples by real-time PCR. b Kaplan–
Meier graph representing the probability of disease-free survival in HNSCC patients from the “Milan-INT” dataset stratified. The log-rank test P value 
reflects the significance of the association between low miR-645 level and disease-free survival. c–e Mature miR-645 levels were compared between 
HNSCC samples with severe histological signs (vascular emboli, perineural invasion, diffuse infiltration) and the tissues with non-severe histological 
signs by real-time PCR
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HNSCC invasion in the cancer cell line HN12. For this 
purpose, we silenced miR-645 and this treatment led to 
an approximately 1.5-fold decline in growth properties 
(Fig. 2c).
Ectopic expression of miR‑645 promotes cancer metastasis
In light of the preceding data, we aimed to determine 
more directly if miR-645 plays a causal role in the aggres-
sive traits of HNSCC cancer cells. We used this cell 
line to investigate how gain or loss of function of miR-
645 impacted cell migration and invasion, which are 
hallmarks of metastatic capacity. In the transwell assays 
shown in Fig. 3b, down regulation of miR-645 in HN12 
cells decreased invasive abilities 1.6-fold compared to 
the same cells expressing miR-NC. We further tested if 
endogenous expression of miR-645 was required for cell 
invasion in HNSCC cancer cell line HN4. For this pur-
pose, we upregulated miR-645 and this treatment led to 
an approximately 1.8-fold augmentation in invasive prop-
erties (Fig. 3a). Furthermore, the pro-migration effects of 
miR-645 were observed in wound-healing assays in HN4 
and HN12 cells (Fig. 3c, d).
Table 1 Associations between miR-645 and clinical parameters (n = 62)
SD standard deviation, T tumor stage, N lymphnode stage
a ∆Ct indicates the difference in the cycle number at which a sample’s fluorescent signal passes a given threshold above baseline (Ct) derived from a specific gene 
compared with that of U6 in tumor tissues
Characteristic No. of patients miR‑645 ∆Cta P
No. % Mean ± SD
Age, years
 ≥60 26 41.9 0.29 ± 0.08 0.173
 <60 36 58.1 0.48 ± 0.11
Sex
 Male 43 69.4 0.37 ± 0.09 0.625
 Female 19 30.6 0.45 ± 0.13
Pathologe grade
 I 26 42.6 0.22 ± 0.076 0.025
 II 27 44.3 0.46 ± 0.12
 III 8 13.1 0.82 ± 0.21
T stage
 T1, 2 27 43.5 0.34 ± 0.08 0.406
 T3, 4 34 54.8 0.46 ± 0.11
N stage
 pN− 28 45.2 0.22 ± 0.05 0.017
 pN+ 34 54.8 0.54 ± 0.12
Site
 Tongue 25 41.7 0.32 ± 0.11 0.514
 Gingival 12 20.0 0.44 ± 0.18
 Cheek 7 11.7 0.35 ± 0.16
 Floor of mouth 11 18.3 0.34 ± 0.15
 Oropharynx 5 8.3 0.80 ± 0.41
Histologic signs of severity (vascular emboli, perineural invasion, diffuse infiltration)
 None 26 41.9 0.28 ± 0.05 0.024
 Presence 21 33.9 0.60 ± 0.13
Smoking history
 Nonsmoker 28 45.2 0.41 ± 0.09 0.452
 Smoker 30 48.4 0.32 ± 0.07
Alcohol history
 Nondrinker 38 61.3 0.41 ± 0.08 0.339
 Drinker 20 32.3 0.29 ± 0.07
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Ectopic expression of miR‑645 promotes single cell clone 
proliferation
Single cell clone proliferation ability is considered to be 
hallmarks of metastatic capacity. We aimed to determine 
more directly if miR-645 improve the single cell clone 
proliferation ability. We used this cell line to investigate 
how gain or loss of function of miR-645 impacted the 
single cell clone proliferation ability. In the clony forma-
tion shown in Fig. 4a, up-regulation of miR-645 in HN4 
cells increased single cell clone proliferation ability 1.5-
fold compared to the same cells expressing miR-NC. 
We further tested if endogenous expression of miR-645 
was required for cell invasion in HNSCC cancer cell line 
HN12. For this purpose, we down-regulated miR-645 and 
this treatment led to an approximately 1.6-fold reduction 
in single cell clone proliferation properties (Fig. 4b).
Discussion
Although a global reduction of miRNA abundance 
appears to be a general trait of human cancers, playing a 
causal role in the metastatic phenotype [11, 12, 31], sev-
eral miRNAs are up-regulated in tumors [10], recently, 
miRNAs have been shown to be related to tumor metas-
tasis [30], providing a new perspective on the metastatic 
process. Nonetheless, The role of miRNAs in HNSCC has 
been widely investigated. Here, we will focus on miRNA-
645 promotes HNSCC cancer metastasis.
In this study, we described for the first time the miR-
645 is markly upregulated in metastatic HNSCC in large 
samples. We also found that miR-645 is closely related 
to the cancer metastasis and miR-645 “high expression” 
group displayed a significantly poorer disease-free sur-
vival rates. The miR-645 promote the HNSCC cells pro-
liferation, invasion, migration and the single cell clone 
proliferation ability. The properties is the malignant char-
acters of oncogenes. We have proven that the down-reg-
ulation of miR-645 is crucial in HNSCC metastasis and 
demonstrated that miR-645 acts as a putative oncogene.
Recently, miRNAs have been proved to be related with 
tumor metastasis [32–34], providing a new perspec-
tive on the metastatic process. Nonetheless, the role 
of miRNAs in HNSCC metastasis is little known. This 
study first proves that miR-645 is up-regulated in meta-
static HNSCC. Aberrant patterns of miRNA expression 
are implicated in human diseases including HNSCC. 
miR-645 plays a variety of important functions in physi-
ology and pathology [22, 24]. Recent literature reports 
that the miR-645 play important effort in the malignant 
Fig. 2 miR-645 promotes HNSCC. a Expression levels of miR-645 in cellular models of metastatic progression were tested by real-time PCR. Values 
related to the nonmetastatic, less aggressive cell line (HN4) are normalised to U6 and shown as the mean and SD. b, c Cell growth curves: prolifera-
tion of phenotypically stable indicated cell lines was monitored by the CCK-8 assay. d Linear regression analyse the correlation between miR-645 
and IFIT2
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Fig. 3 miR-645 promotes cell invasion and migration. a, b Representative pictures of cells migrated through the filter, stained with crystal violet, 
and taken at the same magnification and absolute quantifications as cells that had invaded through the transwell. c, d Wound-healing assay show-
ing that gain of miR-645 promotes cell migration and loss of miR-645 suppresses cell migration
Fig. 4 miR-645 promotes single cell clone proliferation. a, b Representative pictures of single cell clone proliferation, stained with crystal violet, 
colony formation assay in the group of 1 × 105 cells for miR-NC transfected and miR-645-transfected cells
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progressing of ovarian cancer and adenocarcinoma of 
gastric esophagea [23, 25]. As miRNAs function mainly 
through the inhibition of multiple target genes and study 
report that miR-645 inhibits apoptosis by targeting 
tumor suppressor IFIT2 [25]. In our study, the inverse 
correlation between miR-645 and IFIT2 was confirmed 
by real-time PCR in the panel of 127 HNSCC tissues. We 
support that the IFIT2 may be the target gene of miR-645 
(Fig.  2d). Meantime we support that the miRNAs play 
their efforts though the complicate gene net. This result 
may preliminary explain the function of miR-645, but the 
mechanism is still to be research.
Conclusion
In conclusion, our results have proven that miR-645 plays 
a causal role in the metastases of HNSCC. These findings 
have implications for understanding the mechanism of 
HNSCC, and miR-645 may be a valuable maker and tar-
get for prevention or adjuvant therapy in HNSCC.
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